Research Progress of Serum Exosomal MicroRNAs in Non-Small Cell Lung Cancer 
Zhou Bingqian  Tang Xi^{（corresponding author）}

Jingzhou Hospital Affiliated to Yangtze University, Jingzhou City Hubei Province, 434020;

Abstract：Lung cancer is one of the malignant tumors with the highest incidence and mortality rates worldwide, among which approximately 85% are non-small cell lung cancer (NSCLC). Due to the lack of specific clinical manifestations in the early stage of NSCLC, most patients are already at an advanced stage at the time of diagnosis, missing the optimal therapeutic window and resulting in a poor overall prognosis. Exosomes are basically nano-sized extracellular vesicles that can not only pack a wide variety of bioactive molecules inside their lumen, but also display these molecules right on their membrane surface. They are, by nature, tools for shuttling messages between cells, and they can influence and modulate tumor initiation and progression through many different pathways. A growing body of research has now demonstrated that exosome-carried microRNAs (miRNAs) are involved in regulating a whole range of processes in non-small cell lung cancer cells, including invasion, metastasis, angiogenesis, and drug resistance. This review carefully sorts through what exosomal miRNAs actually do in non-small cell lung cancer and the molecular mechanisms behind these processes, with the aim of finding new clues and pointing to new directions—ones that may well provide quite useful ideas for identifying prognostic and diagnostic biomarkers.

Keyword：exosomes; microRNAs; non-small cell lung cancer

References

[1]Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.

[2]Liu S, Xu T, Cao X, Li H, Jin R. Histological transformation in lung cancer: Mechanisms, clinical characteristics, and therapeutic approaches. Biochim Biophys Acta Rev Cancer. 2025;1880(5):189413.

[3]Alsatari ES, Smith KR, Galappaththi SPL, Turbat-Herrera EA, Dasgupta S. The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity. Int J Mol Sci. 2025;26(8).

[4]Yang T, Xiong Y, Zeng Y, Wang Y, Zeng J, Liu J, et al. Current status of immunotherapy for non-small cell lung cancer. Frontiers in Pharmacology. 2022;Volume 13 - 2022.

[5]Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535-46.

[6]Chen H, Wang L, Zeng X, Schwarz H, Nanda HS, Peng X, et al. Exosomes, a New Star for Targeted Delivery. Front Cell Dev Biol. 2021;9:751079.

[7]Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-79.

[8]Kronstein-Wiedemann R, Künzel SR, Thiel J, Tonn T. Role of MiRNA in the Regulation of Blood Group Expression. Transfus Med Hemother. 2024;51(4):237-51.

[9]Li J, Wang J, Chen Z. Emerging role of exosomes in cancer therapy: progress and challenges. Mol Cancer. 2025;24(1):13.

[10]Hsu XR, Wu JE, Wu YY, Hsiao SY, Liang JL, Wu YJ, et al. Exosomal long noncoding RNA MLETA1 promotes tumor progression and metastasis by regulating the miR-186-5p/EGFR and miR-497-5p/IGF1R axes in non-small cell lung cancer. J Exp Clin Cancer Res. 2023;42(1):283.

[11]Yang F, Yan Y, Yang Y, Hong X, Wang M, Yang Z, et al. MiR-210 in exosomes derived from CAFs promotes non-small cell lung cancer migration and invasion through PTEN/PI3K/AKT pathway. Cell Signal. 2020;73:109675.

[12]Xia Y, Wei K, Hu LQ, Zhou CR, Lu ZB, Zhan GS, et al. Exosome-mediated transfer of miR-1260b promotes cell invasion through Wnt/β-catenin signaling pathway in lung adenocarcinoma. J Cell Physiol. 2020;235(10):6843-53.

[13]Kim DH, Park H, Choi YJ, Kang MH, Kim TK, Pack CG, et al. Exosomal miR-1260b derived from non-small cell lung cancer promotes tumor metastasis through the inhibition of HIPK2. Cell Death Dis. 2021;12(8):747.

[14]Yu F, Liang M, Huang Y, Wu W, Zheng B, Chen C. Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling. J Exp Clin Cancer Res. 2021;40(1):179.

[15]Ma Z, Wei K, Yang F, Guo Z, Pan C, He Y, et al. Tumor-derived exosomal miR-3157-3p promotes angiogenesis, vascular permeability and metastasis by targeting TIMP/KLF2 in non-small cell lung cancer. Cell Death Dis. 2021;12(9):840.

[16]Han J, Hu J, Sun F, Bian H, Tang B, Fang X. MicroRNA-20a-5p suppresses tumor angiogenesis of non-small cell lung cancer through RRM2-mediated PI3K/Akt signaling pathway. Mol Cell Biochem. 2021;476(2):689-98.

[17]Fan J, Xu G, Chang Z, Zhu L, Yao J. miR-210 transferred by lung cancer cell-derived exosomes may act as proangiogenic factor in cancer-associated fibroblasts by modulating JAK2/STAT3 pathway. Clin Sci (Lond). 2020;134(7):807-25.

[18]Zhan R, Yu H, Zhang G, Ding Q, Li H, Li X, et al. Exosomal EGFR and miR-381-3P Mediate HPV-16 E7 Oncoprotein-Induced Angiogenesis of Non-Small Cell Lung Cancer. Front Biosci (Landmark Ed). 2024;29(5):189.

[19]Havryliuk V, Wojtowicz K, Gagat M, Żuryń A. Exosome-Mediated Mechanisms of Drug Resistance in Lung Cancer: Molecular Mechanisms and Therapeutic Strategies. Cell Physiol Biochem. 2025;59(3):358-74.

[20]Gerbin E, Rivière GN, Foulon L, Frapart YM, Cottyn B, Pernes M, et al. Tuning the functional properties of lignocellulosic films by controlling the molecular and supramolecular structure of lignin. Int J Biol Macromol. 2021;181:136-49.

[21]Sun B, Hu N, Cong D, Chen K, Li J. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route. Bioengineered. 2021;12(1):3219-28.

[22]Liu J, Xing Y, Rong L. miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol Rep. 2018;39(4):1631-9.

[23]Wang H, Huang H, Wang L, Liu Y, Wang M, Zhao S, et al. Cancer-associated fibroblasts secreted miR-103a-3p suppresses apoptosis and promotes cisplatin resistance in non-small cell lung cancer. Aging (Albany NY). 2021;13(10):14456-68.

[24]Shi L, Zhu W, Huang Y, Zhuo L, Wang S, Chen S, et al. Cancer-associated fibroblast-derived exosomal microRNA-20a suppresses the PTEN/PI3K-AKT pathway to promote the progression and chemoresistance of non-small cell lung cancer. Clin Transl Med. 2022;12(7):e989.

[25]Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, et al. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. Lung Cancer. 2017;113:106-14.

[26]Kalinke L, Thakrar R, Janes SM. The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers. Mol Oncol. 2021;15(10):2544-64.

[27]Zhou T, Ma H, Li Z, Xu Y, Zhao L. Exosomes in lung cancer: a role in early diagnosis. Front Oncol. 2025;15:1599608.

[28]Tang H, Yu D, Zhang J, Wang M, Fu M, Qian Y, et al. The new advance of exosome-based liquid biopsy for cancer diagnosis. J Nanobiotechnology. 2024;22(1):610.

[29]Yu D, Li Y, Wang M, Gu J, Xu W, Cai H, et al. Exosomes as a new frontier of cancer liquid biopsy. Molecular Cancer. 2022;21(1):56.

[30]Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai Y, et al. MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer. PLoS One. 2015;10(8):e0134220.

[31]Guo W, Zhang Y, Zhang Y, Shi Y, Xi J, Fan H, et al. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med. 2015;36(6):1720-6.

[32]Zhang Y, Zhang Y, Yin Y, Li S. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients. Pathol Res Pract. 2019;215(8):152466.

[33]Zhang Y, Xu H. Serum exosomal miR-378 upregulation is associated with poor prognosis in non-small-cell lung cancer patients. J Clin Lab Anal. 2020;34(6):e23237.

[34]Han Z, Li Y, Zhang J, Guo C, Li Q, Zhang X, et al. Tumor-derived circulating exosomal miR-342-5p and miR-574-5p as promising diagnostic biomarkers for early-stage Lung Adenocarcinoma. Int J Med Sci. 2020;17(10):1428-38.

[35]Zhang ZJ, Song XG, Xie L, Wang KY, Tang YY, Yu M, et al. Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer. Exp Biol Med (Maywood). 2020;245(16):1428-36.

[36]Rodríguez-Sanz J, Mincholé Lapuente E, Polanco Alonso D, Viñuales Aranda MD, Marín-Oto M, Domingo Morera JA, et al. Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment. Transl Lung Cancer Res. 2025;14(11):5099-117.

[37]Zhang Z, Ma H, Zheng Y, Wang L, Wang C, Liu Y, et al. Exosomal miR-3126-5p derived from cancer-associated fibroblasts facilitates glycolysis to accelerate NSCLC progression by targeting KLF13 to activate the SH2B1/IRS1 axis. Clin Transl Med. 2025;15(12):e70554.

[38]Yang B, Xin X, Cao X, Nasifu L, Nie Z, He B. The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review. Clinical and Translational Oncology. 2024;26(8):1921-33.

[39]Zheng B, Peng M, Gong J, Li C, Cheng H, Li Y, et al. Circulating exosomal microRNA-4497 as a potential biomarker for metastasis and prognosis in non-small-cell lung cancer. Exp Biol Med (Maywood). 2023;248(16):1403-13.

[40]Xue X, Wang C, Xue Z, Wen J, Han J, Ma X, et al. Exosomal miRNA profiling before and after surgery revealed potential diagnostic and prognostic markers for lung adenocarcinoma. Acta Biochim Biophys Sin (Shanghai). 2020;52(3):281-93.

[41]Liu W, Liu J, Zhang Q, Wei L. Downregulation of serum exosomal miR-216b predicts unfavorable prognosis in patients with non-small cell lung cancer. Cancer Biomark. 2020;27(1):113-20.